Summary latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2020, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
- The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Summary Protagen AG (Protagen) is a medical device company that develops molecular diagnostic and companion diagnostic test equipment.The company’s products include multilisa SSC, multilisa SLE and multilisa RA. It provides products for autoimmune diseases such as rheumatoid arthritis, neuromyelitis optica, systemic...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
17 pages •
By Euromonitor International
• Jan 2021
Natural increase will be the sole driver of population expansion in the Dominican Republic up to 2040. While ageing will be a key trend, with rapid growth in the elderly and a decline in the younger age groups, the country will remain relatively young as birth rates remain comparatively high. Nevertheless, as population composition alters...
16 pages •
By Euromonitor International
• Dec 2020
Positive net migration will be the key driver of population growth in Singapore in 2019-2040. Ageing, compounded by low birth rates and rising longevity, will remain a key demographic trend which is set to transform the consumer landscape further, as well as placing mounting pressure on state resources. As a densely population city-state with...
17 pages •
By Euromonitor International
• Nov 2020
After peaking in 2024, depopulation will occur in Germany up to 2040 as falling net migration rates are no longer able to mitigate increasingly negative natural change. As birth rates drop and longevity climbs, ageing will accelerate transforming consumer trends and putting additional pressure on state resources. Urbanisation will continue...
17 pages •
By Euromonitor International
• Feb 2021
Natural increase will be the sole driver of swift population growth in Pakistan in 2020-2040, as net migration remains negative. Ageing will be quite slow over this timeframe, with the country remaining extremely young in a regional context due to relatively elevated birth rates and low life expectancy. Urbanisation will be swift and the country...
17 pages •
By Euromonitor International
• Jan 2021
Natural increase will be the sole driver of population growth in Morocco in 2019-2040, as net migration remains negative. Ageing will accelerate as birth rates drop further and longevity climbs, transforming consumer trends somewhat as population composition alters. Urbanisation will continue to be swift and Morocco will remain one of the...
17 pages •
By Euromonitor International
• Dec 2020
Positive net migration will be the main driver of UK population growth in 2019-2040. Ageing will be a key demographic trend over this time, transforming consumer trends and putting further pressure on state resources. Immigrants will make up over a tenth of the UK population by 2040, with those from Poland and India continuing to make up the...
17 pages •
By Euromonitor International
• Dec 2020
Natural increase and modest net migration rates should drive population growth in South Africa in 2019-2040. While ageing will be rapid as birth rates decline and longevity rises, South Africa will remain a relatively young country in a global context. Its expanding workforce and increased prosperity should intensify consumer purchasing power...
Healthcare
Diabetes
Pathology
Obesity
Chronic Disease
South Africa
World
Net Migration Rate
Life Expectancy
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.